Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 3—March 2019

Whole-Genome Sequencing of Drug-Resistant Mycobacterium tuberculosis Strains, Tunisia, 2012–2016

Imen BouzouitaComments to Author , Andrea Maurizio Cabibbe, Alberto Trovato, Henda Daroui, Asma Ghariani, Basma Midouni, Leila Essalah, Emna Mehiri, Daniela Maria Cirillo, and Leila Slim Saidi
Author affiliations: National Reference Laboratory for Mycobacteria, Ariana, Tunisia (I. Bouzouita, H. Daroui, A. Ghariani, B. Midouni, L. Essalah, E. Mehiri, L. Slim Saidi); University of Tunis El Manar, Tunis, Tunisia (I. Bouzouita, B. Midouni); San Raffaele Scientific Institute, Milan, Italy (A.M. Cabibbe, A. Trovato, D.M. Cirillo); University of Monastir, Monastir, Tunisia (A. Ghariani, E. Mehiri, L. Slim Saidi)

Main Article

Table 2

Mutations detected in genes conferring resistance to fluoroquinolones, aminoglycosides, and capreomycin in study of drug-resistant Mycobacterium tuberculosis strains, Tunisia, 2012–2016*

No. strains Cluster Resistance to FQ, AG, or CAP on MGIT 960 gyrA gyrB rrs tlyA eis–p
3 1 OFX, LVX, KAN, AMK, CAP Asp94Gly† A1401G†
1 1 OFX, LVX, KAN, AMK, CAP Asp461His/Gly470Cys A1401G†
1 1 OFX, LVX Ala90Val†
1 1 OFX, LVX Asp94Gly†
1 3 OFX, LVX Ser91Pro†
1 Not clustered OFX, LVX, KAN Asp94Ala† Asp461Asn C-14T†
1 Not clustered OFX, LVX, CAP Ser91Pro† INS of 2G†
1 Not clustered OFX, LVX Asp94Ser
1 Not clustered OFX, LVX Ala90Val†
1 Not clustered OFX, LVX Asp461Asn
1 Not clustered OFX, LVX Asp94Tyr†

*Among second-line drugs, 7 strains were pre-XDR (FQ resistant) and 6 were XDR TB strains on MGIT 960. AG, aminoglycosides; AMK, amikacin; CAP, capreomycin; eis-p, eis promoter; FQ, fluoroquinolone; INS, insertion; KAN, kanamycin; LVX, levofloxacin, MGIT 960, Bactec MGIT 960 system (Becton, Dickinson and Company,; OFX, ofloxacin; TB, tuberculosis; XDR, extensively drug resistant.

†High-confidence mutations associated with FQ, AG, or CAP resistance according to (12).

Main Article

  1. World Health Organization. Global Tuberculosis Report. Geneva. Organization. 2018;•••:256.
  2. Roetzer  A, Diel  R, Kohl  TA, Rückert  C, Nübel  U, Blom  J, et al. Whole genome sequencing versus traditional genotyping for investigation of a Mycobacterium tuberculosis outbreak: a longitudinal molecular epidemiological study. PLoS Med. 2013;10:e1001387. DOIPubMedGoogle Scholar
  3. Nikolayevskyy  V, Kranzer  K, Niemann  S, Drobniewski  F. Whole genome sequencing of Mycobacterium tuberculosis for detection of recent transmission and tracing outbreaks: A systematic review. Tuberculosis (Edinb). 2016;98:7785. DOIPubMedGoogle Scholar
  4. Bryant  JM, Schürch  AC, van Deutekom  H, Harris  SR, de Beer  JL, de Jager  V, et al. Inferring patient to patient transmission of Mycobacterium tuberculosis from whole genome sequencing data. BMC Infect Dis. 2013;13:110. DOIPubMedGoogle Scholar
  5. Walker  TM, Ip  CL, Harrell  RH, Evans  JT, Kapatai  G, Dedicoat  MJ, et al. Whole-genome sequencing to delineate Mycobacterium tuberculosis outbreaks: a retrospective observational study. Lancet Infect Dis. 2013;13:13746. DOIPubMedGoogle Scholar
  6. Hatherell  HA, Colijn  C, Stagg  HR, Jackson  C, Winter  JR, Abubakar  I. Interpreting whole genome sequencing for investigating tuberculosis transmission: a systematic review. BMC Med. 2016;14:21. DOIPubMedGoogle Scholar
  7. Kohl  TA, Diel  R, Harmsen  D, Rothgänger  J, Walter  KM, Merker  M, et al. Whole-genome-based Mycobacterium tuberculosis surveillance: a standardized, portable, and expandable approach. J Clin Microbiol. 2014;52:247986. DOIPubMedGoogle Scholar
  8. Papaventsis  D, Casali  N, Kontsevaya  I, Drobniewski  F, Cirillo  DM, Nikolayevskyy  V. Whole genome sequencing of Mycobacterium tuberculosis for detection of drug resistance: a systematic review. Clin Microbiol Infect. 2017;23:618. DOIPubMedGoogle Scholar
  9. Feuerriegel  S, Schleusener  V, Beckert  P, Kohl  TA, Miotto  P, Cirillo  DM, et al. PhyResSE: a Web tool delineating Mycobacterium tuberculosis antibiotic resistance and lineage from whole-genome sequencing data. J Clin Microbiol. 2015;53:190814. DOIPubMedGoogle Scholar
  10. Sekizuka  T, Yamashita  A, Murase  Y, Iwamoto  T, Mitarai  S, Kato  S, et al. TGS-TB: total genotyping solution for Mycobacterium tuberculosis using short read whole genome sequencing. PLoS One. 2015;10:e0142951. DOIPubMedGoogle Scholar
  11. Meftahi  N, Namouchi  A, Mhenni  B, Brandis  G, Hughes  D, Mardassi  H. Evidence for the critical role of a secondary site rpoB mutation in the compensatory evolution and successful transmission of an MDR tuberculosis outbreak strain. J Antimicrob Chemother. 2016;71:32432. DOIPubMedGoogle Scholar
  12. Miotto  P, Tessema  B, Tagliani  E, Chindelevitch  L, Starks  AM, Emerson  C, et al. A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis. Eur Respir J. 2017;50:1701354. DOIPubMedGoogle Scholar
  13. Mardassi  H, Namouchi  A, Haltiti  R, Zarrouk  M, Mhenni  B, Karboul  A, et al. Tuberculosis due to resistant Haarlem strain, Tunisia. Emerg Infect Dis. 2005;11:95761. DOIPubMedGoogle Scholar
  14. Dekhil  N, Meftahi  N, Mhenni  B, Ben Fraj  S, Haltiti  R, Belhaj  S, et al. MDR-TB Outbreak among HIV-Negative Tunisian Patients followed during 11 Years. PLoS One. 2016;11:e0153983. DOIPubMedGoogle Scholar
  15. Ford  CB, Shah  RR, Maeda  MK, Gagneux  S, Murray  MB, Cohen  T, et al. Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nat Genet. 2013;45:78490. DOIPubMedGoogle Scholar

Main Article

Page created: February 19, 2019
Page updated: February 19, 2019
Page reviewed: February 19, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.